Overview

A Study of CTA101 UCAR-T Cell Injection in Patients With Relapsed or Refractory CD19+ B-line Hematological Malignancy

Status:
Recruiting
Trial end date:
2027-05-31
Target enrollment:
Participant gender:
Summary
A study of CTA101 UCAR-T cell injection in patients with relapsed or refractory CD19+ B-line hematological malignancy
Phase:
Early Phase 1
Details
Lead Sponsor:
He Huang
Collaborator:
Nanjing Bioheng Biotech Co., Ltd.